A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Inclusion Criteria

• •Patients aged ≥ 18 years
• •Patients with advanced solid tumors (CRC, melanoma) with documented somatic KRAS or BRAFV600 mutations in tumor tissue. Patients with metastatic pancreatic adenocarcinoma may be enrolled irrespectively of KRAS or BRAFV600 mutational status.
• •Patients must have relapsed or progressed following standard therapy or patients for whom no standard anticancer therapy exists.
• •Measurable disease as determined by RECIST v1.1. World Health Organization (WHO) Performance Status (PS) ≤ 2.
• •Adequate organ function
• •Negative serum pregnancy test